Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life.

@article{Bortel1993NebivololIH,
  title={Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life.},
  author={Luc M A B Van Bortel and J G Breed and J. Joosten and Johannes A. Kragten and F. A.Th. Lustermans and J. M. Mooij},
  journal={Journal of cardiovascular pharmacology},
  year={1993},
  volume={21 6},
  pages={856-62}
}
Nebivolol is a selective beta 1-adrenoceptor antagonist with a particular hemodynamic profile, suggesting an ancillary vasodilating property. The nature of this ancillary property is still unknown. The present double-blind placebo-controlled multicenter study investigated the effect of 4 and 8 weeks treatment with nebivolol 5 mg once daily on blood pressure (BP), heart rate (HR), blood parameters, and ECG. The effect on quality of life perception and the adverse effect profile were also studied… CONTINUE READING